Published in N Engl J Med on July 24, 1997
Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol (2013) 2.73
A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selection. Cell (2013) 2.60
Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology (2006) 2.25
Null association between histology of first and second primary malignancies in men with bilateral testicular germ cell tumors. Am J Epidemiol (2013) 2.00
Newer insights into premeiotic development of germ cells in adult human testis using Oct-4 as a stem cell marker. J Histochem Cytochem (2010) 1.92
Inhibition of transcription by platinum antitumor compounds. Metallomics (2009) 1.88
Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br J Cancer (2010) 1.86
Core 2 N-acetylglucosaminyltransferase-1 expression induces aggressive potential of testicular germ cell tumor. Int J Cancer (2010) 1.58
Consequences of cisplatin binding on nucleosome structure and dynamics. Chem Biol (2010) 1.51
Epigenetics and its role in male infertility. J Assist Reprod Genet (2012) 1.27
Adolescent and adult risk factors for testicular cancer. Nat Rev Urol (2012) 1.22
Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer (1998) 1.21
Characteristic promoter hypermethylation signatures in male germ cell tumors. Mol Cancer (2002) 1.13
Redox state-dependent interaction of HMGB1 and cisplatin-modified DNA. Biochemistry (2011) 1.13
Survival of patients with nonseminomatous germ cell cancer: a review of the IGCC classification by Cox regression and recursive partitioning. Br J Cancer (2004) 1.12
Testicular germ cell tumors: pathogenesis, diagnosis and treatment. Nat Rev Endocrinol (2010) 1.12
Synthetic methods for the preparation of platinum anticancer complexes. Chem Rev (2013) 1.11
Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J Clin Oncol (2009) 1.09
p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci U S A (1998) 1.08
p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS One (2011) 1.06
Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles. Mol Cancer (2007) 1.06
The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer (2005) 1.05
Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol Cancer (2004) 1.04
Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. Br J Cancer (1999) 1.03
First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. Br J Cancer (2003) 1.01
Current management of testicular cancer. Korean J Urol (2013) 0.98
Quality of life of testicular cancer survivors and the relationship with sociodemographics, cancer-related variables, and life events. Support Care Cancer (2005) 0.96
Bilateral synchronous spermatocytic seminoma: a rare case report. Pan Afr Med J (2014) 0.92
The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Support Care Cancer (2005) 0.91
Acute respiratory distress syndrome after chemotherapy for lung metastases from non-seminomatous germ-cell tumors. Support Care Cancer (2003) 0.91
Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer (2004) 0.89
Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. PLoS One (2012) 0.89
Primary yolk sac tumor of seminal vesicle: a case report and literature review. World J Surg Oncol (2012) 0.89
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer (2002) 0.88
Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors. J Exp Clin Cancer Res (2009) 0.88
Cordycepin induced MA-10 mouse Leydig tumor cell apoptosis by regulating p38 MAPKs and PI3K/AKT signaling pathways. Sci Rep (2015) 0.88
Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging (2003) 0.87
Geographic clustering of testicular cancer incidence in the northern part of The Netherlands. Br J Cancer (1999) 0.87
Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer (2002) 0.86
Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors. Neoplasia (2005) 0.86
Genome-wide analysis of germ cell proliferation in C.elegans identifies VRK-1 as a key regulator of CEP-1/p53. Dev Biol (2010) 0.85
Brain metastasis from non-seminomatous germ cell tumors of the testis: indications for aggressive treatment. Neurosurg Rev (2005) 0.85
Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck. Clin Med Insights Ther (2013) 0.85
Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1. Neoplasia (2004) 0.85
A miR-199a/miR-214 self-regulatory network via PSMD10, TP53 and DNMT1 in testicular germ cell tumor. Sci Rep (2014) 0.84
DNA methylation profiles delineate epigenetic heterogeneity in seminoma and non-seminoma. Br J Cancer (2011) 0.84
Testis cancer. Postgrad Med J (2007) 0.84
cAMP signalling protects proximal tubular epithelial cells from cisplatin-induced apoptosis via activation of Epac. Br J Pharmacol (2012) 0.84
MAPK15 upregulation promotes cell proliferation and prevents DNA damage in male germ cell tumors. Oncotarget (2016) 0.84
Quality of life of survivors of testicular germ cell cancer: a review of the literature. Support Care Cancer (2004) 0.83
Canine classical seminoma: a specific malignant type with human classifications is highly correlated with tumor angiogenesis. BMC Cancer (2010) 0.83
TRA-1-60(+), SSEA-4(+), POU5F1(+), SOX2(+), NANOG(+) Clones of Pluripotent Stem Cells in the Embryonal Carcinomas of the Testes. J Stem Cell Res Ther (2013) 0.83
Serum tumor markers in the evaluation of male germ cell tumors. Nat Rev Urol (2010) 0.83
A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. Hematol Oncol Clin North Am (2011) 0.82
125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer. Br J Cancer (1999) 0.82
Cancer in first-degree relatives and risk of testicular cancer in Denmark. Int J Cancer (2011) 0.82
Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours. Br J Cancer (2003) 0.81
1,25-dihydroxyvitamin D and PTHrP mediated malignant hypercalcemia in a seminoma. BMC Endocr Disord (2014) 0.81
Fatty acid synthase overexpression in adult testicular germ cell tumors: potential role in the progression of non-seminomatous germ cell tumors. Virchows Arch (2013) 0.81
Management of the primary malignant mediastinal germ cell tumors: experience with 54 patients. Diagn Pathol (2014) 0.80
Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors. Virchows Arch (2003) 0.80
Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors. Ann Surg (2005) 0.79
Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors. Diagn Pathol (2015) 0.79
Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. Invest New Drugs (2000) 0.79
Longstanding hydrocele in adult Black Africans: Is preoperative scrotal ultrasound justified? Niger Med J (2011) 0.79
Brain Metastases as Presenting Feature in 'Burned Out' Testicular Germ Cell Tumor. Cureus (2016) 0.78
Maternal body mass index and risk of testicular cancer in male offspring: a systematic review and meta-analysis. Cancer Epidemiol (2010) 0.78
Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. Br J Cancer (2010) 0.78
Very late relapse of germ cell tumor as a teratoma: a case report and review of the literature. J Surg Case Rep (2014) 0.78
Treatment outcome of patients with extragonadal nonseminomatous germ cell tumors: the Saitama Cancer Center experience. Int J Clin Oncol (2012) 0.78
Clinical and genetic aspects of testicular germ cell tumours. Hered Cancer Clin Pract (2008) 0.78
Combining cohort and period methods for retrospective time trend analyses of long-term cancer patient survival rates. Br J Cancer (2003) 0.78
Predictive value of GGN and CAG repeat polymorphisms of androgen receptors in testicular cancer: a meta-analysis. Oncotarget (2016) 0.78
Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors. Invest New Drugs (2004) 0.77
Spontaneous metastasis in mouse models of testicular germ-cell tumours. Int J Androl (2011) 0.77
Contrasting effects of Deadend1 (Dnd1) gain and loss of function mutations on allelic inheritance, testicular cancer, and intestinal polyposis. BMC Genet (2013) 0.77
A decision-analytic approach to define poor prognosis patients: a case study for non-seminomatous germ cell cancer patients. BMC Med Inform Decis Mak (2008) 0.77
Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors. Invest New Drugs (2007) 0.77
Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance. Open Access J Urol (2011) 0.76
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J Cancer Res Clin Oncol (2004) 0.76
Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer. Braz J Med Biol Res (2014) 0.76
Non-Seminomatous Germ Cell Tumor Metastasis to the Jaw: An Imaging Case Report. Iran J Radiol (2016) 0.75
Application of the International Germ Cell Consensus Classification to the Nova Scotia population of patients with germ cell tumours. Can Urol Assoc J (2009) 0.75
Rapid progression of a germ cell tumor encasing the inferior vena cava and aorta following a radical orchiectomy. Rare Tumors (2013) 0.75
PET/CT in paediatric malignancies - An update. Indian J Med Paediatr Oncol (2016) 0.75
The utilization of oncology web-based resources in Spanish-speaking Internet users. Am J Clin Oncol (2012) 0.75
The histologic features of intratubular germ cell neoplasia and its correlation with tumor behavior. Investig Clin Urol (2016) 0.75
Circulating tumor cells in germ cell tumors: are those biomarkers of real prognostic value? A review. Clujul Med (2016) 0.75
Detection of human endogenous retrovirus type K-specific transcripts in testicular parenchyma and testicular germ cell tumors of adolescents and adults: clinical and biological implications. Am J Pathol (1998) 0.75
A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy. J Nanobiotechnology (2015) 0.75
A 20-year retrospective study of histopathologic patterns of gonadal germ cell tumors in males in the University of Benin Teaching Hospital. Niger Med J (2016) 0.75
Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach. PLoS One (2015) 0.75
Late relapse of germ-cell tumor. Rev Urol (2003) 0.75
Radical resection of a late-relapsed testicular germ cell tumour: hepatectomy, cavotomy, and thrombectomy. Case Rep Surg (2014) 0.75
Analysis of Isocitrate Dehydrogenase -2 (IDH-2) Activity in Human Serum as a Biomarker in Chemotherapy Patients of Breast Carcinoma: A Case-Control Study. J Clin Diagn Res (2017) 0.75
The role of high-dose chemotherapy in relapsed germ cell tumors. World J Urol (2004) 0.75
Primary retroperitoneal mature cystic teratoma (dermoid cyst) in a 51-year-old male:Case report and historical literature review. SAGE Open Med Case Rep (2017) 0.75
In vitro pharmacological study of monomeric platinum(III) hematoporphyrin IX complexes. Invest New Drugs (2010) 0.75
A postoperative prognostic nomogram for renal cell carcinoma. J Urol (2001) 3.01
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst (1994) 2.92
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol (1993) 2.42
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol (2010) 2.06
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol (1996) 1.85
Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol (1992) 1.50
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol (1996) 1.49
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol (1990) 1.38
A recurring translocation, t(11;22)(p13;q11.2), characterizes intra-abdominal desmoplastic small round-cell tumors. Cancer Genet Cytogenet (1993) 1.35
Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol (1997) 1.34
Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol (1994) 1.33
Targeted therapy for metastatic renal cell carcinoma. Br J Cancer (2006) 1.29
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer (2011) 1.29
Hemorrhage: a complication of metastatic testicular choriocarcinoma. Urology (1987) 1.28
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol (1993) 1.24
Surgery for a post-chemotherapy residual mass in seminoma. J Urol (1997) 1.20
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer (1995) 1.19
Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol (1993) 1.18
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer (2010) 1.13
The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res (2004) 1.12
Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol (2012) 1.12
Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol (2001) 1.11
Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer (1992) 1.02
Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a. Clin Cancer Res (1999) 1.02
Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst (1993) 1.01
Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene (2012) 1.00
Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst (1994) 0.98
Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol (2001) 0.97
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Ann Oncol (2014) 0.94
Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer (1994) 0.93
Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors. J Natl Cancer Inst (1990) 0.93
Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol (2001) 0.92
Novel investigative approaches for advanced renal cell carcinoma. Semin Oncol (2000) 0.90
Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma. Br J Cancer (2012) 0.87
Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clin Cancer Res (1996) 0.87
Poor prognosis germ cell tumors: current status and future directions. Semin Oncol (1998) 0.86
Infrequent ras oncogene point mutations in renal cell carcinoma. J Urol (1990) 0.85
Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res (1998) 0.85
Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. Cancer (1994) 0.84
Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs (1994) 0.84
Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Invest New Drugs (1994) 0.84
Aminopeptidase A expression and enzymatic activity in primary human renal cancers. Int J Oncol (1998) 0.82
Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors. Semin Oncol (1992) 0.81
Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site. Semin Oncol (1993) 0.81
Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst (1993) 0.81
t(12;22)(q13;q13) and trisomy 8 are nonrandom aberrations in clear-cell sarcoma. Cancer Genet Cytogenet (1992) 0.80
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α. Br J Cancer (2012) 0.80
Management of renal cell carcinoma. Oncology (Williston Park) (2000) 0.80
Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. Invest New Drugs (2000) 0.79
Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Invest New Drugs (1995) 0.79
Risk assessment for metastatic testis cancer. Urol Clin North Am (1998) 0.79
Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. Invest New Drugs (1992) 0.78
Metastatic germ cell tumors: modeling for response to chemotherapy. J Clin Oncol (1998) 0.78
Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy. Cancer Res (1992) 0.78
Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin. Cancer Treat Rep (1987) 0.77
Expression of the retinoblastoma gene product in renal tumors. Anticancer Res (1996) 0.77
A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs (1997) 0.76
all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. Cancer (1995) 0.76
Adjuvant chemotherapy for testicular cancer. Surg Oncol Clin N Am (1997) 0.76
Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. Invest New Drugs (2001) 0.75
Defining new standards for adjuvant therapy of testis cancer: a reply. J Clin Oncol (1996) 0.75
Optimal treatment for advanced seminoma? Cancer (1993) 0.75
Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol (1997) 0.75
Selecting patients with cisplatin-resistant germ cell tumors for high-dose chemotherapy. J Clin Oncol (1996) 0.75
Calvert's formula for dosing carboplatin: overview and concerns of applicability in high-dose setting. J Natl Cancer Inst (2000) 0.75
A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J Clin Oncol (1992) 0.75
The current status of salvage chemotherapy for patients with cisplatin-resistant germ cell tumors. Cancer Invest (1993) 0.75
The evolving role of chemotherapy of germ cell tumors. Recent Results Cancer Res (1993) 0.75
The management of patients with advanced germ cell tumors. Seminoma and nonseminoma. Urol Clin North Am (1994) 0.75
A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma. Invest New Drugs (1999) 0.75
Chemotherapy for germ cell tumors. Urol Clin North Am (1987) 0.75
A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer. Invest New Drugs (1993) 0.75
Germ cell tumors. Curr Ther Endocrinol Metab (1994) 0.75
Germ cell tumors. Curr Ther Endocrinol Metab (1997) 0.75
Poor-risk germ cell tumors. Recent developments. Urol Clin North Am (1998) 0.75